127 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Ccnd1tm1Dsn/Ccnd1tm1Dsn Cdkn1btm1Mlf/Cdkn1btm1Mlf involves: 129 * C57BL/6	abnormal corpus luteum morphology	J:66707
	abnormal reflex	J:66707
	normal craniofacial phenotype	J:66707
	disorganized retina layers	J:66707
	normal endocrine/exocrine gland phenotype	J:66707
	enlarged spleen	J:66707
	enlarged testis	J:66707
	enlarged thymus	J:66707
	female infertility	J:66707
	increased body weight	J:66707
	increased pituitary adenoma incidence	J:66707
	normal mortality/aging	J:66707
	thymus hyperplasia	J:66707
Ccnd3tm1Pisc/Ccnd3tm1Pisc Cdkn1btm1Mlf/Cdkn1btm1Mlf involves: 129S4/SvJaeSor	abnormal bone marrow cell physiology	J:192031
	decreased double-positive T cell number	J:192031
	decreased T cell proliferation	J:192031
	thymus hypoplasia	J:192031
Ccnd3tm1Pisc/Ccnd3tm1Pisc Cdkn1btm1Mlf/Cdkn1btm1Mlf Rb1tm2Brn/Rb1tm2Brn Tg(Mx1-cre)1Cgn/0 involves: 129S4/SvJaeSor * C57BL/6 * CBA	normal immune system phenotype	J:192031
Cdk2tm1Kald/Cdk2tm1Kald Cdk4tm1Kiyo/Cdk4tm1Kiyo Cdkn1btm1Ako/Cdkn1btm1Ako involves: 129S1/Sv * C57BL/6	decreased cell proliferation	J:108720
	lethality throughout fetal growth and development, complete penetrance	J:108720
Cdkn1atm1Tyj/Cdkn1atm1Tyj Cdkn1btm1Ako/Cdkn1btm1Ako involves: 129S1/Sv * 129S2/SvPas	abnormal junctional epithelium morphology	J:102001
	decreased circulating testosterone level	J:115443
	decreased prostate gland anterior lobe weight	J:115443
	decreased prostate gland dorsolateral lobe weight	J:115443
	decreased prostate gland ventral lobe weight	J:115443
	decreased seminal vesicle weight	J:115443
	hepatic steatosis	J:118516
	impaired glucose tolerance	J:118516
	increased body weight	J:115443, J:118516
	increased brain weight	J:118516
	increased brown adipose tissue amount	J:118516
	increased circulating cholesterol level	J:118516
	increased food intake	J:118516
	increased inguinal fat pad weight	J:118516
	increased kidney weight	J:118516
	increased lean body mass	J:118516
	increased parametrial fat pad weight	J:118516
	increased total body fat amount	J:118516
	increased white fat cell number	J:118516
	insulin resistance	J:118516
Cdkn1atm1Tyj/Cdkn1atm1Tyj Cdkn1btm1Mlf/Cdkn1btm1Mlf involves: 129S2/SvPas * 129S4/SvJaeSor	abnormal crypts of Lieberkuhn morphology	J:111081
	abnormal enterocyte proliferation	J:111081
	abnormal ileum morphology	J:111081
	abnormal response to injury	J:111081
	abnormal small intestinal villus morphology	J:111081
Cdkn1btm1Ako/Cdkn1b+ KitW-v/KitW-v involves: 129S1/Sv * C57BL/6J	abnormal ovary physiology	J:236161
	increased ovary adenoma incidence	J:236161
	increased ovary tumor incidence	J:236161
	premature death	J:236161
Cdkn1btm1Ako/Cdkn1b+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0 129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp	increased thyroid adenoma incidence	J:165293
	increased thyroid carcinoma incidence	J:165293
	premature death	J:165293
Cdkn1btm1Ako/Cdkn1btm1Ako Cdkn2ctm1Yxi/Cdkn2ctm1Yxi involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2	ataxia	J:50053
	decreased tumor-free survival time	J:50053
	dehydration	J:50053
	enlarged adrenal glands	J:50053
	enlarged heart	J:50053
	enlarged pituitary gland	J:50053
	enlarged spleen	J:50053
	enlarged testis	J:50053
	enlarged thymus	J:50053
	increased carcinoma incidence	J:50053
	increased pituitary adenoma incidence	J:50053
	pituitary intermediate lobe hyperplasia	J:50053
	weight loss	J:50053
Cdkn1btm1Ako/Cdkn1btm1Ako KitW-v/KitW-v involves: 129S1/Sv * C57BL/6J	abnormal ovary physiology	J:236161
	increased ovary adenoma incidence	J:236161
	increased ovary tumor incidence	J:236161
Cdkn1btm1Ako/Cdkn1btm1Ako Men1tm1.1Ctre/Men1+ involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6	increased adrenal gland tumor incidence	J:120835
	increased lung adenoma incidence	J:120835
	increased pancreas tumor incidence	J:120835
	increased parathyroid gland tumor incidence	J:120835
	increased pituitary gland tumor incidence	J:120835
	increased testis tumor incidence	J:120835
	increased thyroid tumor incidence	J:120835
	increased tumor incidence	J:120835
Cdkn1btm1Ako/Cdkn1btm1Ako Men1tm1.1Ctre/Men1tm1.1Ctre involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6	embryonic lethality, complete penetrance	J:120835
Cdkn1btm1Ako/Cdkn1btm1Ako Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0 129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp	premature death	J:165293
	respiratory distress	J:165293
	thyroid gland hyperplasia	J:165293
Cdkn1btm1Jro/Cdkn1btm1Jro Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N	abnormal tumor pathology	J:318035
	decreased tumor growth/size	J:318035
	normal growth/size/body region phenotype	J:318035
	increased osteosarcoma incidence	J:318035
	increased tumor-free survival time	J:318035
	normal reproductive system phenotype	J:318035
Cdkn1btm1Kin/Cdkn1b+ Leprdb/Leprdb involves: C57BL/6J * C57BLKS/J	abnormal pancreatic islet morphology	J:96047
	decreased body temperature	J:96047
	hyperglycemia	J:96047
	hyperlipidemia	J:96047
	increased circulating insulin level	J:96047
	increased pancreatic beta cell number	J:96047
	obese	J:96047
	polyphagia	J:96047
Cdkn1btm1Kin/Cdkn1b+ Irs2tm1Mfw/Irs2tm1Mfw involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	enlarged pancreatic islets	J:96047
	increased circulating glucose level	J:96047
	increased circulating insulin level	J:96047
	increased pancreatic beta cell number	J:96047
Cdkn1btm1Kin/Cdkn1btm1Kin Irs2tm1Mfw/Irs2tm1Mfw involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	enlarged pancreatic islets	J:96047
	increased circulating glucose level	J:96047
	increased circulating insulin level	J:96047
	increased pancreatic beta cell number	J:96047
Cdkn1btm1Kin/Cdkn1btm1Kin Leprdb/Leprdb involves: C57BL/6J * C57BLKS/J	abnormal pancreatic islet morphology	J:96047
	decreased body temperature	J:96047
	hyperlipidemia	J:96047
	increased circulating insulin level	J:96047
	increased pancreatic beta cell number	J:96047
	obese	J:96047
	polyphagia	J:96047
Cdkn1btm1Kin/Cdkn1btm1Kin Skp2tm1Kin/Skp2tm1Kin involves: 129P2/OlaHsd * C57BL/6	normal immune system phenotype	J:74265
Cdkn1btm1Kin/Cdkn1btm1Kin Zfp949tm1Htno/Zfp949tm1Htno involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	abnormal embryo turning	J:259302
	decreased cell proliferation	J:259302
	decreased embryo size	J:259302
	embryonic lethality during organogenesis, complete penetrance	J:259302
Cdkn1btm1Mlf/Cdkn1b+ Ptch1tm1Mps/Ptch1+ involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6	abnormal cerebellar molecular layer	J:205254
	hydrocephaly	J:205254
	increased gastrointestinal tumor incidence	J:205254
	increased hemangiosarcoma incidence	J:205254
	increased lymphoma incidence	J:205254
	increased medulloblastoma incidence	J:205254
	increased rhabdomyosarcoma incidence	J:205254
	increased tumor incidence	J:205254
	premature death	J:205254
Cdkn1btm1Mlf/Cdkn1b+ Myctm1Atp/Myc+ involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N	decreased body size	J:73369
Cdkn1btm1Mlf/Cdkn1b+ Crebbptm1Jvd/Crebbptm1Jvd Tg(MMTV-cre)4Mam/0 involves: 129 * C57BL/6 * CBA * FVB	increased T cell derived lymphoma incidence	J:88323
Cdkn1btm1Mlf/Cdkn1b+ Vsx2tm1.1Eml/Vsx2tm1.1Eml involves: 129 * C57BL/6	abnormal eye morphology	J:190452
Cdkn1btm1Mlf/Cdkn1b+ Tg(TG-TPR/NTRK1)#Rstn/0 involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J	increased thyroid carcinoma incidence	J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf Cdkn2dtm1Maro/Cdkn2dtm1Maro involves: 129X1/SvJ * C57BL/6	abnormal behavior	J:58522
	abnormal mitosis	J:58522
	abnormal neuron morphology	J:58522
	bradykinesia	J:58522
	cachexia	J:58522
	decreased body size	J:58522
	dehydration	J:58522
	impaired righting response	J:58522
	increased cell proliferation	J:58522
	increased mitotic index	J:58522
	increased neuron apoptosis	J:58522
	limb grasping	J:58522
	muscle hypertonia	J:58522
	normal nervous system phenotype	J:58522
	paresis	J:58522
	photosensitivity	J:58522
	postnatal lethality, complete penetrance	J:58522
	respiratory distress	J:58522
	seizures	J:58522
	tremors	J:58522
	weight loss	J:58522
Cdkn1btm1Mlf/Cdkn1btm1Mlf Myctm1Atp/Myc+ involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N	decreased body size	J:73369
	decreased T cell proliferation	J:73369
Cdkn1btm1Mlf/Cdkn1btm1Mlf Myctm1Atp/Myctm1Atp involves: 129P2/OlaHsd * 129S4/SvJaeSor * FVB/N	prenatal lethality, complete penetrance	J:73369
Cdkn1btm1Mlf/Cdkn1btm1Mlf Nkx3-1tm1.1Saa/Nkx3-1tm1.1Saa involves: 129S4/SvJaeSor * C57BL/6 * FVB/N	increased prostate intraepithelial neoplasia incidence	J:89571
	preneoplasia	J:89571
Cdkn1btm1Mlf/Cdkn1btm1Mlf Ptch1tm1Mps/Ptch1+ involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6	abnormal cerebellar molecular layer	J:205254
	hydrocephaly	J:205254
	increased gastrointestinal tumor incidence	J:205254
	increased hemangiosarcoma incidence	J:205254
	increased lymphoma incidence	J:205254
	increased medulloblastoma incidence	J:205254
	increased rhabdomyosarcoma incidence	J:205254
	increased tumor incidence	J:205254
	premature death	J:205254
Cdkn1btm1Mlf/Cdkn1btm1Mlf Rbx1Gt(XB674)Byg/Rbx1Gt(XB674)Byg involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J	normal cellular phenotype	J:147759
	embryonic lethality during organogenesis, complete penetrance	J:147759
Cdkn1btm1Mlf/Cdkn1btm1Mlf Tg(KRT5-CDK4)2303Mlrp/0 involves: 129S4/SvJae * C57BL/6 * FVB * SENCAR * SSIN	enlarged thymus	J:107588
	thymus hyperplasia	J:107588
Cdkn1btm1Mlf/Cdkn1btm1Mlf Tg(MMTV-vHaras)SH1Led/0 involves: 129S4/SvJaeSor * C57BL/6J * CD-1	increased tumor growth/size	J:80271
Cdkn1btm1Mlf/Cdkn1btm1Mlf Tg(TG-TPR/NTRK1)#Rstn/0 involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J	increased thyroid carcinoma incidence	J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J	decreased tumor-free survival time	J:87536
	increased sarcoma incidence	J:87536
	increased T cell derived lymphoma incidence	J:87536
	increased tumor incidence	J:87536
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd involves: C3H * C57BL/6J * NIH	decreased tumor-free survival time	J:87536
	increased sarcoma incidence	J:87536
	increased T cell derived lymphoma incidence	J:87536
	increased tumor incidence	J:87536
Cdkn1btm2Kin/Cdkn1btm2Kin Rassf5tm1Kina/Rassf5tm1Kina involves: C57BL/6 * CBA	normal immune system phenotype	J:168749
	increased urine protein level	J:168749
	normal neoplasm	J:168749
Cdkn1btm3Jro/Cdkn1b+ involves: 129S4/SvJaeSor	increased body size	J:103819
Cdkn1btm3Jro/Cdkn1btm3Jro involves: 129S4/SvJaeSor	enlarged spleen	J:103819
	enlarged thymus	J:103819
	increased body size	J:103819
	increased body weight	J:103819
Fgfr1tm1Upir/Fgfr1tm1Upir Fgfr2tm1Dor/Fgfr2tm1Dor Gt(ROSA)26Sortm1(Cdkn1b,EGFP)Dor/Gt(ROSA)26Sor+ Myl2tm1(cre)Krc/Myl2+ involves: 129/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6	heart hypoplasia	J:131577
	thin ventricular wall	J:131577